Mechanism of IL-10-Induced T Cell Inactivation in Allergic Inflammation and Normal Response to Allergens

Background: Induction of specific unresponsiveness (tolerance/anergy) in peripheral T cells and recovery by cytokines from the tissue microenvironment represent two key steps in specific immunotherapy (SIT) with whole allergen or antigenic T cell peptides. Methods: Antigen-specific T cell responses and molecular mechanisms of T cell inactivation were investigated during conventional SIT, T cell epitope peptide immunotherapy and natural exposure to bee venom in allergic and hyperimmune individuals. Results: T cell unresponsiveness, initiated by autocrine action of IL-10, is characterized by suppressed proliferative and cytokine responses. The unresponsive T cells can be reactivated by different cytokines that may mimic the microenvironmental cytokine influence. IL-10 initiates peripheral tolerance by blocking the CD28 costimulatory signal in T cells. Coprecipitation experiments reveal that upon stimulation CD28 and IL-10 receptor are physically associated in T cells. Accordingly, IL-10 binding to its receptor inhibits CD28 tyrosine phosphorylation, the initial step of the CD28 signaling pathway. This leads to inhibition of phosphatidylinositol 3-kinase p85 binding to CD28. IL-10 only affects T cells that receive a stimulation with low numbers of triggered T cell receptors and that require costimulatory signals by CD28. Conclusion: These data demonstrate the pivotal role of autocrine IL-10 and the interaction of its receptor with CD28 in the induction of T cell tolerance as an immunoregulatory mechanism controlling antigen-specific T cell responses.

[1]  C. Akdis,et al.  A molecular basis for T cell suppression by IL‐10: CD28‐associated IL‐10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3‐kinase binding , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  C. Akdis,et al.  IL‐10 directly acts on T cells by specifically altering the CD28 co‐stimulation pathway , 2000, European journal of immunology.

[3]  C. Akdis,et al.  IL‐10‐induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  C. Akdis,et al.  Determinants and Mechanisms of Human Immune Responses to Bee Venom Phospholipase A2 , 1998, International Archives of Allergy and Immunology.

[5]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[6]  C. Akdis,et al.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.

[7]  C. Akdis,et al.  Glucocorticoids inhibit human antigen‐specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro , 1997, European journal of immunology.

[8]  M. Goldman,et al.  IL-10: a potential therapy for allergic inflammation? , 1997, Immunology today.

[9]  C. Akdis,et al.  Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. , 1997, The Journal of allergy and clinical immunology.

[10]  M. Jutel,et al.  Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  C. Akdis,et al.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. , 1996, The Journal of clinical investigation.

[12]  M. Jordana,et al.  Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. , 1996, The Journal of clinical investigation.

[13]  H. Mosbech,et al.  Position Paper: Immunotherapy with Hymenoptera venoms , 1993 .